Switch theme
Sign up to access all valuation multiples
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
1995
n/a
LTM Revenue $325M
LTM EBITDA $62.3M
$716M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guizhou Sanli has a last 12-month revenue (LTM) of $325M and a last 12-month EBITDA of $62.3M.
In the most recent fiscal year, Guizhou Sanli achieved revenue of $299M and an EBITDA of $58.0M.
Guizhou Sanli expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guizhou Sanli valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $325M | XXX | $299M | XXX | XXX | XXX |
| Gross Profit | $226M | XXX | $209M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $62.3M | XXX | $58.0M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $49.0M | XXX | $48.6M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $41.3M | XXX | $38.2M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $12.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Guizhou Sanli's stock price is CNY 12 (or $2).
Guizhou Sanli has current market cap of CNY 4.8B (or $672M), and EV of CNY 5.1B (or $716M).
See Guizhou Sanli trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $716M | $672M | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Guizhou Sanli has market cap of $672M and EV of $716M.
Guizhou Sanli's trades at 2.4x EV/Revenue multiple, and 12.4x EV/EBITDA.
Equity research analysts estimate Guizhou Sanli's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guizhou Sanli has a P/E ratio of 16.3x.
See valuation multiples for Guizhou Sanli and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $672M | XXX | $672M | XXX | XXX | XXX |
| EV (current) | $716M | XXX | $716M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 11.5x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBIT | 14.6x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.3x | XXX | 17.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 83.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuizhou Sanli's last 12 month revenue growth is 16%
Guizhou Sanli's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Guizhou Sanli's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guizhou Sanli's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Guizhou Sanli and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guizhou Sanli acquired XXX companies to date.
Last acquisition by Guizhou Sanli was XXXXXXXX, XXXXX XXXXX XXXXXX . Guizhou Sanli acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Guizhou Sanli founded? | Guizhou Sanli was founded in 1995. |
| Where is Guizhou Sanli headquartered? | Guizhou Sanli is headquartered in China. |
| Is Guizhou Sanli publicy listed? | Yes, Guizhou Sanli is a public company listed on SHG. |
| What is the stock symbol of Guizhou Sanli? | Guizhou Sanli trades under 603439 ticker. |
| When did Guizhou Sanli go public? | Guizhou Sanli went public in 2020. |
| Who are competitors of Guizhou Sanli? | Similar companies to Guizhou Sanli include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Guizhou Sanli? | Guizhou Sanli's current market cap is $672M |
| What is the current revenue of Guizhou Sanli? | Guizhou Sanli's last 12 months revenue is $325M. |
| What is the current revenue growth of Guizhou Sanli? | Guizhou Sanli revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Guizhou Sanli? | Current revenue multiple of Guizhou Sanli is 2.2x. |
| Is Guizhou Sanli profitable? | Yes, Guizhou Sanli is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Guizhou Sanli? | Guizhou Sanli's last 12 months EBITDA is $62.3M. |
| What is Guizhou Sanli's EBITDA margin? | Guizhou Sanli's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Guizhou Sanli? | Current EBITDA multiple of Guizhou Sanli is 11.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
